Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, viruses, or fungi; however, bacterial pneumonia is the most common form occurring in adults. Center for Disease Control and Prevention (CDC) recommends administration of two pneumococcal vaccines.

The global Pneumonia Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Pneumonia Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pneumonia Vaccine.

Report Scope

The Pneumonia Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pneumonia Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Pneumonia Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Pneumonia Vaccine Market Report

Report Metric	Details
Report Name	Pneumonia Vaccine Market
CAGR	5%
Segment by Type	Pneumococcal Conjugate Vaccine (PCV13) Pneumococcal Polysaccharide Vaccine (PPSV23) Other
Segment by Application	Pneumonia Meningitis Sepsis
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Pfizer Inc., Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Serum Institute of India Pvt. Ltd., Johnson & Johnson, Astellas Pharma Inc., Astrazeneca Plc., CSL Limited, Emergent Biosolutions, Walvax Biotechnology, Royal (Wuxi) Bio-Pharmaceutical, Zhifei Biologic
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pneumonia Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pneumonia Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Pneumonia Vaccine Market report?

Ans: The main players in the Pneumonia Vaccine Market are Pfizer Inc., Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Serum Institute of India Pvt. Ltd., Johnson & Johnson, Astellas Pharma Inc., Astrazeneca Plc., CSL Limited, Emergent Biosolutions, Walvax Biotechnology, Royal (Wuxi) Bio-Pharmaceutical, Zhifei Biologic

What are the Application segmentation covered in the Pneumonia Vaccine Market report?

Ans: The Applications covered in the Pneumonia Vaccine Market report are Pneumonia, Meningitis, Sepsis

What are the Type segmentation covered in the Pneumonia Vaccine Market report?

Ans: The Types covered in the Pneumonia Vaccine Market report are Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23), Other

1 Pneumonia Vaccine Market Overview

1.1 Product Overview and Scope of Pneumonia Vaccine

1.2 Pneumonia Vaccine Segment by Type

1.2.1 Global Pneumonia Vaccine Market Value Comparison by Type (2024-2030)

1.2.2 Pneumococcal Conjugate Vaccine (PCV13)

1.2.3 Pneumococcal Polysaccharide Vaccine (PPSV23)

1.2.4 Other

1.3 Pneumonia Vaccine Segment by Application

1.3.1 Global Pneumonia Vaccine Market Value by Application: (2024-2030)

1.3.2 Pneumonia

1.3.3 Meningitis

1.3.4 Sepsis

1.4 Global Pneumonia Vaccine Market Size Estimates and Forecasts

1.4.1 Global Pneumonia Vaccine Revenue 2019-2030

1.4.2 Global Pneumonia Vaccine Sales 2019-2030

1.4.3 Global Pneumonia Vaccine Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Pneumonia Vaccine Market Competition by Manufacturers

2.1 Global Pneumonia Vaccine Sales Market Share by Manufacturers (2019-2024)

2.2 Global Pneumonia Vaccine Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Pneumonia Vaccine Average Price by Manufacturers (2019-2024)

2.4 Global Pneumonia Vaccine Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Pneumonia Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Pneumonia Vaccine, Product Type & Application

2.7 Pneumonia Vaccine Market Competitive Situation and Trends

2.7.1 Pneumonia Vaccine Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Pneumonia Vaccine Players Market Share by Revenue

2.7.3 Global Pneumonia Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Pneumonia Vaccine Retrospective Market Scenario by Region

3.1 Global Pneumonia Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Pneumonia Vaccine Global Pneumonia Vaccine Sales by Region: 2019-2030

3.2.1 Global Pneumonia Vaccine Sales by Region: 2019-2024

3.2.2 Global Pneumonia Vaccine Sales by Region: 2025-2030

3.3 Global Pneumonia Vaccine Global Pneumonia Vaccine Revenue by Region: 2019-2030

3.3.1 Global Pneumonia Vaccine Revenue by Region: 2019-2024

3.3.2 Global Pneumonia Vaccine Revenue by Region: 2025-2030

3.4 North America Pneumonia Vaccine Market Facts & Figures by Country

3.4.1 North America Pneumonia Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Pneumonia Vaccine Sales by Country (2019-2030)

3.4.3 North America Pneumonia Vaccine Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Pneumonia Vaccine Market Facts & Figures by Country

3.5.1 Europe Pneumonia Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Pneumonia Vaccine Sales by Country (2019-2030)

3.5.3 Europe Pneumonia Vaccine Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Pneumonia Vaccine Market Facts & Figures by Country

3.6.1 Asia Pacific Pneumonia Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Pneumonia Vaccine Sales by Country (2019-2030)

3.6.3 Asia Pacific Pneumonia Vaccine Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Pneumonia Vaccine Market Facts & Figures by Country

3.7.1 Latin America Pneumonia Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Pneumonia Vaccine Sales by Country (2019-2030)

3.7.3 Latin America Pneumonia Vaccine Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Pneumonia Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Pneumonia Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Pneumonia Vaccine Sales by Country (2019-2030)

3.8.3 Middle East and Africa Pneumonia Vaccine Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Pneumonia Vaccine Sales by Type (2019-2030)

4.1.1 Global Pneumonia Vaccine Sales by Type (2019-2024)

4.1.2 Global Pneumonia Vaccine Sales by Type (2025-2030)

4.1.3 Global Pneumonia Vaccine Sales Market Share by Type (2019-2030)

4.2 Global Pneumonia Vaccine Revenue by Type (2019-2030)

4.2.1 Global Pneumonia Vaccine Revenue by Type (2019-2024)

4.2.2 Global Pneumonia Vaccine Revenue by Type (2025-2030)

4.2.3 Global Pneumonia Vaccine Revenue Market Share by Type (2019-2030)

4.3 Global Pneumonia Vaccine Price by Type (2019-2030)

5 Segment by Application

5.1 Global Pneumonia Vaccine Sales by Application (2019-2030)

5.1.1 Global Pneumonia Vaccine Sales by Application (2019-2024)

5.1.2 Global Pneumonia Vaccine Sales by Application (2025-2030)

5.1.3 Global Pneumonia Vaccine Sales Market Share by Application (2019-2030)

5.2 Global Pneumonia Vaccine Revenue by Application (2019-2030)

5.2.1 Global Pneumonia Vaccine Revenue by Application (2019-2024)

5.2.2 Global Pneumonia Vaccine Revenue by Application (2025-2030)

5.2.3 Global Pneumonia Vaccine Revenue Market Share by Application (2019-2030)

5.3 Global Pneumonia Vaccine Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Pfizer Inc.

6.1.1 Pfizer Inc. Corporation Information

6.1.2 Pfizer Inc. Description and Business Overview

6.1.3 Pfizer Inc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Pfizer Inc. Pneumonia Vaccine Product Portfolio

6.1.5 Pfizer Inc. Recent Developments/Updates

6.2 Glaxosmithkline Plc.

6.2.1 Glaxosmithkline Plc. Corporation Information

6.2.2 Glaxosmithkline Plc. Description and Business Overview

6.2.3 Glaxosmithkline Plc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolio

6.2.5 Glaxosmithkline Plc. Recent Developments/Updates

6.3 Merck & Co., Inc.

6.3.1 Merck & Co., Inc. Corporation Information

6.3.2 Merck & Co., Inc. Description and Business Overview

6.3.3 Merck & Co., Inc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Merck & Co., Inc. Pneumonia Vaccine Product Portfolio

6.3.5 Merck & Co., Inc. Recent Developments/Updates

6.4 Sanofi Pasteur

6.4.1 Sanofi Pasteur Corporation Information

6.4.2 Sanofi Pasteur Description and Business Overview

6.4.3 Sanofi Pasteur Pneumonia Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Sanofi Pasteur Pneumonia Vaccine Product Portfolio

6.4.5 Sanofi Pasteur Recent Developments/Updates

6.5 Serum Institute of India Pvt. Ltd.

6.5.1 Serum Institute of India Pvt. Ltd. Corporation Information

6.5.2 Serum Institute of India Pvt. Ltd. Description and Business Overview

6.5.3 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolio

6.5.5 Serum Institute of India Pvt. Ltd. Recent Developments/Updates

6.6 Johnson & Johnson

6.6.1 Johnson & Johnson Corporation Information

6.6.2 Johnson & Johnson Description and Business Overview

6.6.3 Johnson & Johnson Pneumonia Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Johnson & Johnson Pneumonia Vaccine Product Portfolio

6.6.5 Johnson & Johnson Recent Developments/Updates

6.7 Astellas Pharma Inc.

6.6.1 Astellas Pharma Inc. Corporation Information

6.6.2 Astellas Pharma Inc. Description and Business Overview

6.6.3 Astellas Pharma Inc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Astellas Pharma Inc. Pneumonia Vaccine Product Portfolio

6.7.5 Astellas Pharma Inc. Recent Developments/Updates

6.8 Astrazeneca Plc.

6.8.1 Astrazeneca Plc. Corporation Information

6.8.2 Astrazeneca Plc. Description and Business Overview

6.8.3 Astrazeneca Plc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Astrazeneca Plc. Pneumonia Vaccine Product Portfolio

6.8.5 Astrazeneca Plc. Recent Developments/Updates

6.9 CSL Limited

6.9.1 CSL Limited Corporation Information

6.9.2 CSL Limited Description and Business Overview

6.9.3 CSL Limited Pneumonia Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.9.4 CSL Limited Pneumonia Vaccine Product Portfolio

6.9.5 CSL Limited Recent Developments/Updates

6.10 Emergent Biosolutions

6.10.1 Emergent Biosolutions Corporation Information

6.10.2 Emergent Biosolutions Description and Business Overview

6.10.3 Emergent Biosolutions Pneumonia Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Emergent Biosolutions Pneumonia Vaccine Product Portfolio

6.10.5 Emergent Biosolutions Recent Developments/Updates

6.11 Walvax Biotechnology

6.11.1 Walvax Biotechnology Corporation Information

6.11.2 Walvax Biotechnology Pneumonia Vaccine Description and Business Overview

6.11.3 Walvax Biotechnology Pneumonia Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Walvax Biotechnology Pneumonia Vaccine Product Portfolio

6.11.5 Walvax Biotechnology Recent Developments/Updates

6.12 Royal (Wuxi) Bio-Pharmaceutical

6.12.1 Royal (Wuxi) Bio-Pharmaceutical Corporation Information

6.12.2 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Description and Business Overview

6.12.3 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolio

6.12.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments/Updates

6.13 Zhifei Biologic

6.13.1 Zhifei Biologic Corporation Information

6.13.2 Zhifei Biologic Pneumonia Vaccine Description and Business Overview

6.13.3 Zhifei Biologic Pneumonia Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Zhifei Biologic Pneumonia Vaccine Product Portfolio

6.13.5 Zhifei Biologic Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Pneumonia Vaccine Industry Chain Analysis

7.2 Pneumonia Vaccine Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Pneumonia Vaccine Production Mode & Process

7.4 Pneumonia Vaccine Sales and Marketing

7.4.1 Pneumonia Vaccine Sales Channels

7.4.2 Pneumonia Vaccine Distributors

7.5 Pneumonia Vaccine Customers

8 Pneumonia Vaccine Market Dynamics

8.1 Pneumonia Vaccine Industry Trends

8.2 Pneumonia Vaccine Market Drivers

8.3 Pneumonia Vaccine Market Challenges

8.4 Pneumonia Vaccine Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Serum Institute of India Pvt. Ltd

Emergent Biosolutions

Walvax Biotechnology

Royal (Wuxi) Bio-Pharmaceutical

Zhifei Biologic

List of Tables

Table 1. Global Pneumonia Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Pneumonia Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Pneumonia Vaccine Market Competitive Situation by Manufacturers in 2023

Table 4. Global Pneumonia Vaccine Sales (K Doses) of Key Manufacturers (2019-2024)

Table 5. Global Pneumonia Vaccine Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Pneumonia Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Pneumonia Vaccine Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Pneumonia Vaccine Average Price (USD/Dose) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Pneumonia Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Pneumonia Vaccine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Pneumonia Vaccine, Product Type & Application

Table 12. Global Key Manufacturers of Pneumonia Vaccine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Pneumonia Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pneumonia Vaccine as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Pneumonia Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Pneumonia Vaccine Sales by Region (2019-2024) & (K Doses)

Table 18. Global Pneumonia Vaccine Sales Market Share by Region (2019-2024)

Table 19. Global Pneumonia Vaccine Sales by Region (2025-2030) & (K Doses)

Table 20. Global Pneumonia Vaccine Sales Market Share by Region (2025-2030)

Table 21. Global Pneumonia Vaccine Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Pneumonia Vaccine Revenue Market Share by Region (2019-2024)

Table 23. Global Pneumonia Vaccine Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Pneumonia Vaccine Revenue Market Share by Region (2025-2030)

Table 25. North America Pneumonia Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Pneumonia Vaccine Sales by Country (2019-2024) & (K Doses)

Table 27. North America Pneumonia Vaccine Sales by Country (2025-2030) & (K Doses)

Table 28. North America Pneumonia Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Pneumonia Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Pneumonia Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Pneumonia Vaccine Sales by Country (2019-2024) & (K Doses)

Table 32. Europe Pneumonia Vaccine Sales by Country (2025-2030) & (K Doses)

Table 33. Europe Pneumonia Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Pneumonia Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Pneumonia Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Pneumonia Vaccine Sales by Region (2019-2024) & (K Doses)

Table 37. Asia Pacific Pneumonia Vaccine Sales by Region (2025-2030) & (K Doses)

Table 38. Asia Pacific Pneumonia Vaccine Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Pneumonia Vaccine Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Pneumonia Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Pneumonia Vaccine Sales by Country (2019-2024) & (K Doses)

Table 42. Latin America Pneumonia Vaccine Sales by Country (2025-2030) & (K Doses)

Table 43. Latin America Pneumonia Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Pneumonia Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Pneumonia Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Pneumonia Vaccine Sales by Country (2019-2024) & (K Doses)

Table 47. Middle East & Africa Pneumonia Vaccine Sales by Country (2025-2030) & (K Doses)

Table 48. Middle East & Africa Pneumonia Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Pneumonia Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Pneumonia Vaccine Sales (K Doses) by Type (2019-2024)

Table 51. Global Pneumonia Vaccine Sales (K Doses) by Type (2025-2030)

Table 52. Global Pneumonia Vaccine Sales Market Share by Type (2019-2024)

Table 53. Global Pneumonia Vaccine Sales Market Share by Type (2025-2030)

Table 54. Global Pneumonia Vaccine Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Pneumonia Vaccine Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Pneumonia Vaccine Revenue Market Share by Type (2019-2024)

Table 57. Global Pneumonia Vaccine Revenue Market Share by Type (2025-2030)

Table 58. Global Pneumonia Vaccine Price (USD/Dose) by Type (2019-2024)

Table 59. Global Pneumonia Vaccine Price (USD/Dose) by Type (2025-2030)

Table 60. Global Pneumonia Vaccine Sales (K Doses) by Application (2019-2024)

Table 61. Global Pneumonia Vaccine Sales (K Doses) by Application (2025-2030)

Table 62. Global Pneumonia Vaccine Sales Market Share by Application (2019-2024)

Table 63. Global Pneumonia Vaccine Sales Market Share by Application (2025-2030)

Table 64. Global Pneumonia Vaccine Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Pneumonia Vaccine Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Pneumonia Vaccine Revenue Market Share by Application (2019-2024)

Table 67. Global Pneumonia Vaccine Revenue Market Share by Application (2025-2030)

Table 68. Global Pneumonia Vaccine Price (USD/Dose) by Application (2019-2024)

Table 69. Global Pneumonia Vaccine Price (USD/Dose) by Application (2025-2030)

Table 70. Pfizer Inc. Corporation Information

Table 71. Pfizer Inc. Description and Business Overview

Table 72. Pfizer Inc. Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 73. Pfizer Inc. Pneumonia Vaccine Product

Table 74. Pfizer Inc. Recent Developments/Updates

Table 75. Glaxosmithkline Plc. Corporation Information

Table 76. Glaxosmithkline Plc. Description and Business Overview

Table 77. Glaxosmithkline Plc. Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 78. Glaxosmithkline Plc. Pneumonia Vaccine Product

Table 79. Glaxosmithkline Plc. Recent Developments/Updates

Table 80. Merck & Co., Inc. Corporation Information

Table 81. Merck & Co., Inc. Description and Business Overview

Table 82. Merck & Co., Inc. Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 83. Merck & Co., Inc. Pneumonia Vaccine Product

Table 84. Merck & Co., Inc. Recent Developments/Updates

Table 85. Sanofi Pasteur Corporation Information

Table 86. Sanofi Pasteur Description and Business Overview

Table 87. Sanofi Pasteur Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 88. Sanofi Pasteur Pneumonia Vaccine Product

Table 89. Sanofi Pasteur Recent Developments/Updates

Table 90. Serum Institute of India Pvt. Ltd. Corporation Information

Table 91. Serum Institute of India Pvt. Ltd. Description and Business Overview

Table 92. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 93. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product

Table 94. Serum Institute of India Pvt. Ltd. Recent Developments/Updates

Table 95. Johnson & Johnson Corporation Information

Table 96. Johnson & Johnson Description and Business Overview

Table 97. Johnson & Johnson Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 98. Johnson & Johnson Pneumonia Vaccine Product

Table 99. Johnson & Johnson Recent Developments/Updates

Table 100. Astellas Pharma Inc. Corporation Information

Table 101. Astellas Pharma Inc. Description and Business Overview

Table 102. Astellas Pharma Inc. Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 103. Astellas Pharma Inc. Pneumonia Vaccine Product

Table 104. Astellas Pharma Inc. Recent Developments/Updates

Table 105. Astrazeneca Plc. Corporation Information

Table 106. Astrazeneca Plc. Description and Business Overview

Table 107. Astrazeneca Plc. Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 108. Astrazeneca Plc. Pneumonia Vaccine Product

Table 109. Astrazeneca Plc. Recent Developments/Updates

Table 110. CSL Limited Corporation Information

Table 111. CSL Limited Description and Business Overview

Table 112. CSL Limited Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 113. CSL Limited Pneumonia Vaccine Product

Table 114. CSL Limited Recent Developments/Updates

Table 115. Emergent Biosolutions Corporation Information

Table 116. Emergent Biosolutions Description and Business Overview

Table 117. Emergent Biosolutions Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 118. Emergent Biosolutions Pneumonia Vaccine Product

Table 119. Emergent Biosolutions Recent Developments/Updates

Table 120. Walvax Biotechnology Corporation Information

Table 121. Walvax Biotechnology Description and Business Overview

Table 122. Walvax Biotechnology Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 123. Walvax Biotechnology Pneumonia Vaccine Product

Table 124. Walvax Biotechnology Recent Developments/Updates

Table 125. Royal (Wuxi) Bio-Pharmaceutical Corporation Information

Table 126. Royal (Wuxi) Bio-Pharmaceutical Description and Business Overview

Table 127. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 128. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product

Table 129. Royal (Wuxi) Bio-Pharmaceutical Recent Developments/Updates

Table 130. Zhifei Biologic Corporation Information

Table 131. Zhifei Biologic Description and Business Overview

Table 132. Zhifei Biologic Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 133. Zhifei Biologic Pneumonia Vaccine Product

Table 134. Zhifei Biologic Recent Developments/Updates

Table 135. Key Raw Materials Lists

Table 136. Raw Materials Key Suppliers Lists

Table 137. Pneumonia Vaccine Distributors List

Table 138. Pneumonia Vaccine Customers List

Table 139. Pneumonia Vaccine Market Trends

Table 140. Pneumonia Vaccine Market Drivers

Table 141. Pneumonia Vaccine Market Challenges

Table 142. Pneumonia Vaccine Market Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Pneumonia Vaccine

Figure 2. Global Pneumonia Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Pneumonia Vaccine Market Share by Type in 2023 & 2030

Figure 4. Pneumococcal Conjugate Vaccine (PCV13) Product Picture

Figure 5. Pneumococcal Polysaccharide Vaccine (PPSV23) Product Picture

Figure 6. Other Product Picture

Figure 7. Global Pneumonia Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 8. Global Pneumonia Vaccine Market Share by Application in 2023 & 2030

Figure 9. Pneumonia

Figure 10. Meningitis

Figure 11. Sepsis

Figure 12. Global Pneumonia Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Pneumonia Vaccine Market Size (2019-2030) & (US$ Million)

Figure 14. Global Pneumonia Vaccine Sales (2019-2030) & (K Doses)

Figure 15. Global Pneumonia Vaccine Average Price (USD/Dose) & (2019-2030)

Figure 16. Pneumonia Vaccine Report Years Considered

Figure 17. Pneumonia Vaccine Sales Share by Manufacturers in 2023

Figure 18. Global Pneumonia Vaccine Revenue Share by Manufacturers in 2023

Figure 19. The Global 5 and 10 Largest Pneumonia Vaccine Players: Market Share by Revenue in 2023

Figure 20. Pneumonia Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 21. Global Pneumonia Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 22. North America Pneumonia Vaccine Sales Market Share by Country (2019-2030)

Figure 23. North America Pneumonia Vaccine Revenue Market Share by Country (2019-2030)

Figure 24. U.S. Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Canada Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Europe Pneumonia Vaccine Sales Market Share by Country (2019-2030)

Figure 27. Europe Pneumonia Vaccine Revenue Market Share by Country (2019-2030)

Figure 28. Germany Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. France Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. U.K. Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Italy Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Russia Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Pneumonia Vaccine Sales Market Share by Region (2019-2030)

Figure 34. Asia Pacific Pneumonia Vaccine Revenue Market Share by Region (2019-2030)

Figure 35. China Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Japan Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. South Korea Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. India Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Australia Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Taiwan Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Indonesia Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Thailand Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Malaysia Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Philippines Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Latin America Pneumonia Vaccine Sales Market Share by Country (2019-2030)

Figure 46. Latin America Pneumonia Vaccine Revenue Market Share by Country (2019-2030)

Figure 47. Mexico Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Brazil Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Argentina Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Middle East & Africa Pneumonia Vaccine Sales Market Share by Country (2019-2030)

Figure 51. Middle East & Africa Pneumonia Vaccine Revenue Market Share by Country (2019-2030)

Figure 52. Turkey Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Saudi Arabia Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. U.A.E Pneumonia Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 55. Global Sales Market Share of Pneumonia Vaccine by Type (2019-2030)

Figure 56. Global Revenue Market Share of Pneumonia Vaccine by Type (2019-2030)

Figure 57. Global Pneumonia Vaccine Price (USD/Dose) by Type (2019-2030)

Figure 58. Global Sales Market Share of Pneumonia Vaccine by Application (2019-2030)

Figure 59. Global Revenue Market Share of Pneumonia Vaccine by Application (2019-2030)

Figure 60. Global Pneumonia Vaccine Price (USD/Dose) by Application (2019-2030)

Figure 61. Pneumonia Vaccine Value Chain

Figure 62. Pneumonia Vaccine Production Process

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Distributors Profiles

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions